Iterum Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Iterum Therapeutics plc (ITRM) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-24.77-38.37-44.43-91.56-52.01-103.13-77.06
Depreciation & Amortization0.282.941.802.100.160.510.14
Stock Based Compensation0.360.7822.114.322.760.000.00
Change in Working Capital-12.733.242.31-0.44-24.5617.90-1.60
Change in Accounts Payable-4.752.221.900.06-14.670.000.00
Change in Other Working Capital-7.990.270.938.14-9.770.000.00
Other Operating Activities10.09-7.95-2.418.148.192.920.68
Net Cash from Operating Activities-26.77-39.33-18.47-15.84-54.53-81.92-77.25
Investing Activities
Capital Expenditures0.000.01-0.06-0.06-0.010.02-0.09
Purchases of Investments-12.3923.3514.02-67.030.000.000.00
Sales/Maturities of Investments30.6023.3559.7312.500.0040.13-8.57
Net Cash from Investing Activities18.2123.3413.96-54.60-0.0140.10-8.66
Financing Activities
Debt Repayment0.000.00-2.25-6.52-6.23-1.030.00
Common Stock Issued26.691.030.4389.6458.373.04107.69
Other Financing Activities0.000.000.000.0011.590.000.00
Net Cash from Financing Activities26.691.03-1.8283.1364.482.06122.20
Summary
Effect of Forex Changes on Cash-0.08-0.06-0.050.00-0.01-0.02-0.11
Net Change in Cash18.05-14.96-6.3812.699.93-39.7836.29
Cash at Beginning of Period6.1121.1327.5114.824.8944.678.49
Cash at End of Period24.166.1121.1327.5114.824.8944.67
Free Cash Flow-26.77-39.34-18.54-15.90-54.54-81.95-77.34
Supplemental Disclosures
Interest Paid0.000.000.020.421.001.400.81
Income Taxes Paid0.220.400.820.440.120.410.35